Biotech Options Buzz: UTHR, NMRA, EWTXSchaeffers Research · Sep 18, 2026
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire · Aug 14, 2026
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026GlobeNewsWire · Jul 27, 2026Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.24 | -$0.23 | Beat |
| May 7, 2026 | -$0.32 | -$0.30 | Beat |
| Mar 16, 2026 | -$0.34 | -$0.35 | Miss |
| Nov 6, 2025 | -$0.34 | -$0.35 | Miss |
| Aug 6, 2025 | -$0.38 | -$0.33 | Beat |
| May 12, 2025 | -$0.40 | -$0.42 | Miss |